We recently reported two naturally occurring polymorphisms of the human serotonin 1A receptor: glycine22 → serine (Ser22) and isoleucine28 → valine (Val28) (Kobilka et al. 1987; Chanda et al. 1993) coded by an intronless gene located on chromosome 5 at 5q11.2-q13 (Kobilka et al. 1987) . Like other members of the G-protein-coupled receptor family (Dohlman et al. 1991) , the 5-HT 1A receptor consists of seven transmembrane hydrophobic domains, with an extracellular aminoterminal domain and a cytoplasmic carboxyl-terminus. By coupling with the G i/o family of heterotrimeric G proteins, the 5-HT 1A receptor has been shown to either inhibit or activate adenylate cyclase activity, open potassium channels, close calcium channels, and inhibit phosphatidylinositol turnover (reviewed in Boess and Martin 1994). The 5-HT 1A receptor is expressed both presynaptically on the cell bodies and the dendrites of serotonergic neurons located in the raphe nuclei and postsynaptically with the highest density in the limbic system (Zifa and Fillon 1992; Burnet et al. 1995) .
The human serotonin 1A (5-HT 1A ) receptor is a protein of 422 amino acids (Kobilka et al. 1987; Chanda et al. 1993) coded by an intronless gene located on chromosome 5 at 5q11.2-q13 (Kobilka et al. 1987) . Like other members of the G-protein-coupled receptor family (Dohlman et al. 1991) , the 5-HT 1A receptor consists of seven transmembrane hydrophobic domains, with an extracellular aminoterminal domain and a cytoplasmic carboxyl-terminus. By coupling with the G i/o family of heterotrimeric G proteins, the 5-HT 1A receptor has been shown to either inhibit or activate adenylate cyclase activity, open potassium channels, close calcium channels, and inhibit phosphatidylinositol turnover (reviewed in Boess and Martin 1994) . The 5-HT 1A receptor is expressed both presynaptically on the cell bodies and the dendrites of serotonergic neurons located in the raphe nuclei and postsynaptically with the highest density in the limbic system (Zifa and Fillon 1992; Burnet et al. 1995) .
The 5-HT 1A receptor is believed to play a role in a variety of behaviors, such as aggression, sexual behavior, and appetite control, and in several psychiatric disorders, such as mood disorders, anxiety disorders, anorexia ner-vosa, schizophrenia, and alcoholism (Zifa and Fillon 1992) . Several lines of evidence indicate that 5-HT 1A receptor agonists have anxiolytic, antiaggressive, and antidepressive properties (Newman et al. 1993; De Vry 1995) . Furthermore, desensitization of the presynaptic 5-HT 1A receptors has been reported after chronic administration of selective serotonin reuptake inhibitors (SSRIs), whereas long-term treatment with various classes of tricyclic antidepressant drugs (TCAs) or repeated electroconvulsive therapy have been shown to sensitize postsynaptic 5-HT 1A receptors (Newman et al. 1993; Blier and de Montigny 1994) . Thus, structural variants of the 5-HT 1A receptor could alter its functional properties and lead to changes in behavior or drug responsiveness.
We recently reported two naturally occurring polymorphisms of the human 5-HT 1A receptor gene, resulting in substitution of glycine to serine at amino acid 22 (Ser22) and isoleucine to valine at amino acid 28 (Val28) (Nakhai et al. 1995) . Both the Gly22 and Ile28 residues are located in the putative amino-terminal extracellular domain of the receptor (Kobilka et al. 1987) . The Ser22 variant was found only in a Finnish population sample at a frequency of 0.2%, whereas the Val28 variant was identified at a higher frequency (0.55%) and in different populations (Nakhai et al. 1995; Bergen et al. 1996) . Erdmann et al. (1995) have also observed Val28 among patients affected by schizophrenia, bipolar affective disorder, and Tourette's syndrome, but found no difference in frequency between patients and controls. Interestingly, another naturally occurring polymorphism of the 5-HT 1A receptor has been recently described in the putative amino-terminal extracellular domain of the receptor at amino acid 16 (proline to leucine) in a Japanese population sample (Harada et al. 1996) .
It is possible that 5-HT 1A receptor variants affect the pharmacological and regulatory properties of the 5-HT 1A receptor. Brüss et al. (1995) recently showed no difference in the pharmacological profiles of the wild type (WT) 5-HT 1A receptor and the Val28 variant transiently expressed in COS-7 cells. Nevertheless, naturally occurring variants in the extracellular amino-terminus of the human ␤ 2 -adrenergic receptor, which shares 43% amino acid identity with the 5-HT 1A receptor (Kobilka et al. 1987) , did not alter ligand affinity, but they altered longterm agonist-promoted down-regulation and functional desensitization (Green et al. 1994 (Green et al. , 1995 . Due to receptor down-regulation, the number of cellular receptors is decreased after prolonged exposure (hours) to agonist. This process plays an important role in cellular desensitization reducing physiological responses despite the continuous presence of the stimulus (Collins et al. 1992) . Several lines of evidence indicate that 5-HT 1A receptor down-regulation and desensitization are tightly related to the mechanism of antidepressant and anxiolytic drug action (Newman et al. 1993; Blier and de Montigny 1994) . To investigate the functional and regulatory significance of the Ser22 and Val28 polymorphisms, these naturally occurring variants were stably expressed in Chinese Hamster Ovary (CHO-K1) cells. This study demonstrates that Ser22 is capable of attenuating agonist-mediated receptor down-regulation and desensitization.
MATERIALS AND METHODS

Construct, Transfection, and Cell Culture
DNA manipulations, plasmid construction and cloning were performed according to Sambrook et al. (1989) . A clone containing the full length 5-HT 1A receptor gene was isolated by plaque hybridization from a human genomic -DASH library (Stratagene, La Jolla, CA), using a probe derived from the human genomic clone G-21 (Kobilka et al. 1987 ) supplied by Dr. M.G. Caron. A 4200 bp Bam H I-Bam H I fragment containing the 5-HT 1A receptor gene was isolated from the clone and inserted into Bam H I linearized pGEM-3Zf( ϩ ) to yield p5-HT 1A . A 1566 bp Xba I-Bam H I fragment of p5-HT 1A containing the complete 5-HT 1A receptor coding sequence was cloned into the Bam H I linearized eukaryotic expression vector pCDNA3 (Invitrogen, San Diego, CA) to yield p5-HT 1A WT. The fragment containing the 5-HT 1A receptor coding sequence was inserted in the sense orientation as confirmed by dideoxy sequencing. Nucleotide substitutions at codons 64 and 82 of p5-HT 1A WT were generated by in vitro site-directed mutagenesis (Kunkel 1985) using oligonucleotides SER22, 5 Ј -AGT-GTTGCCGCTGGTCTCAAAGG-3 Ј , and VAL28, 5 Ј -CACGTCGGAGACACCAGTAGTGTT-3 Ј , to form the plasmids p5-HT 1A SER22 and p5-HT 1A VAL28, respectively. The entire 5-HT 1A coding and adjacent sequences of plasmids p5-HT 1A WT, p5-HT 1A SER22, and p5-HT 1A VAL28 were confirmed by dideoxy sequencing.
p5-HT 1A WT, p5-HT 1A SER22, and p5-HT 1A VAL28 were stably transfected into CHO-K1 cells (ATCC, Rockville, MD) by Lipofectamine (Life Technologies, Gaithesburg, MD) according to the manufacturer's protocol. Clones resistant to 500 g/ml G-418 were assayed for expression of 5-HT 1A receptor mRNA by slot blot hybridizaton (data not shown). Clones expressing high levels of 5-HT 1A receptor mRNA were screened for binding of the high-affinity 5-HT 1A agonist [
Cell lines expressing 400-1000 fmol 5-HT 1A receptor/mg protein were selected for further studies.
Cells were grown in adherent culture at 37 Њ C and 5% CO2 in Ham's F-12 media (Life Technologies, Gaithesburg, MD) supplemented with 10% fetal bovine serum (FBS), 146 g/ml L-glutamine, 500 g/ml G-418, 50 U/ ml penicillin, and 50 g/ml streptomycin. Then 24 h before harvesting the cells, the medium was replaced with medium without antibiotics containing 10% charcoaldextran-treated fetal bovine serum (CDFBS).
Radioligand Binding Studies
Nearly confluent CHO-K1 cells were washed with calcium and magnesium-free phosphate buffered saline (PBS), scraped in ice-cold PBS and centrifuged at 2000 g for 10 min at 4 Њ C. Cells were homogenized in 25 ml of 5 mmol/L Tris-HCl buffer (pH 7.4), containing 5 mmol/L EDTA and centrifuged at 48,000 g for 20 min at 4 Њ C. The resulting pellet was resuspended in 50 mmol/L TrisHCl, pH 7.4, incubated at 37 Њ C with constant agitation for 15 min to destroy any endogenous 5-HT, and centrifuged as above. This step was repeated. Finally, membrane pellets were stored at -80 Њ C.
Equilibrium saturation experiments were performed as follows: membrane suspensions (approximately, 60 g protein /ml) were incubated with 0.2-15 nmol/L [ 3 H]-8-OH-DPAT (specific activity 235 Ci/mmol; Amersham, Arlington Heights, IL) in a final volume of 1 ml of assay buffer (50 mM Tris-HCl, pH 7.4) for 20 min at 37 Њ C. Then 10 mol/L 5-HT was used to define nonspecific binding. Displacement studies were carried out at 1 nmol/L [ 3 H]-8-OH-DPAT in the presence of 12 concentrations of the unlabeled displacer drug. Membranes were incubated at 37 Њ C for 20 min. The reaction was stopped by dilution in ice-cold assay buffer followed by rapid vacuum filtration through Whatman GF/C glass fiber filters. The filters were washed twice with 5 ml of ice-cold assay buffer. Radioactivity was measured in a Beckman LS 6000IC liquid scintillation counter at 55% efficiency.
Protein concentration was determined according to the method of Bradford (1976) using ␥ -globulin as the standard.
cAMP Assay
Samples were prepared according to Mak et al. (1996) with slight modifications. Briefly, cells were grown for 48 h in 96-well plates in Ham's F-12 medium containing 10% CDFBS. Cells were washed three times for 5 min with plain medium and incubated at 37 Њ C with Earle's Balanced Salt Solution (EBSS) containing 0.1 mmol/L ascorbic acid, 100 mol/L forskolin (FSK), and 5-HT ranging from 1 nmol/L to 3 mol/L. After 30-min incubation, the medium was removed and 100 l/well 3% perchloric acid was added. Cells were scraped from the wells and 40 l/well 15% potassium bicarbonate was added to neutralize the samples. The 96-well plates were then centrifuged at 800 g for 10 min at 4 Њ C. Then 50 l supernatant from each well were collected and assayed for cAMP accumulation using a radioassay kit (Diagnostic Products Corporation, Los Angeles, CA) according to the manufacturer's protocol. Results were expressed as pmol of cAMP accumulated/10 5 cells/min. 
Receptor Down-regulation and Desensitization
RESULTS
Pharmacological Characterization of WT, Ser22, and Val28 5-HT 1A Receptors
Clones expressing 965Ϯ120 fmol WT 5-HT 1A receptor/ mg membrane protein, 433Ϯ87 fmol Ser22 5-HT 1A receptor/mg membrane protein and 751Ϯ115 fmol Val28 5-HT 1A receptor/mg membrane (mean Ϯ SEM, n ϭ 6) were selected for the study. 
Agonist-Promoted Down-regulation
To study the long-term agonist-promoted down-regulation of the receptor, CHO-K1 cells expressing either WT, Ser22, or Val28 5-HT 1A receptors were incubated for 24 h with various concentrations of the selective 5-HT 1A agonist 8-OH-DPAT. The maximal reduction in the density of 5-HT 1A receptors was observed at 100 mol/L 8-OH-DPAT and the receptor down-regulation was abolished in presence of the selective 5-HT 1A antagonist (ϩ)-WAY-100135 (Figure 2) . Therefore, 100 mol/ L 8-OH-DPAT was routinely used for the preincubation. Cells expressing either WT or Val28 and incubated for 24 h with 100 mol/L 8-OH-DPAT showed a statistically significant decrease in 5-HT 1A binding sites, whereas Ser22 displayed no significant down-regulation (Table 2) . No change in K D for both WT and variant 5-HT 1A receptors was observed between controls and pretreated cells ( Table 2) . As shown in Figure 3 , the degree of down-regulation after incubation of the cells with 100 mol/L 8-OH-DPAT for 24 and 48 h was significantly lower for Ser22, as compared with the WT 5-HT 1A receptor. To rule out the possibility that the lack of down-regulation in the cells expressing the Ser22 variant reflected some peculiarities of the individual clone studied, the long-term agonist-promoted down- 
DISCUSSION
The aim of this study was to investigate the consequences of naturally occurring variants of the human 5-HT 1A receptor on its functional and regulatory properties. For this purpose, WT, Ser22, and Val28 5-HT 1A receptors were stably expressed in CHO-K1 cells. These cells do not ordinarily express any 5-HT receptor and, thus, are useful for pharmacological and functional studies of transfected 5-HT 1A receptors (Raymond 1991; Raymond et al. 1992; Newman-Tancredi et al. 1992) . (Hoyer et al. 1986; De Vivo and Maayani 1986; Dumuis et al. 1988; Marazziti et al. 1994 ). It was not surprising that WT, Ser22, and Val28 5-HT 1A receptors displayed similar ligand-binding characteristics and showed no difference in coupling to the inhibition of adenylate cyclase activity. Indeed, the regions of the 5-HT 1A receptor protein which are thought to be most important for these functions are the transmembrane hydrophobic domains and their connecting loops, rather than the putative amino-terminal extracellular domain where the Ser22 and Val28 amino acid substitutions are located (Dohlman et al. 1991; Peroutka 1994) . Although the pharmacological and functional profiles of WT, Ser22, and Val28 receptors were similar, the long-term agonist-promoted down-regulation properties were remarkably different. The 24-h preincubation of the cells expressing the WT 5-HT 1A receptor or the Val28 variant with increasing concentrations of 8-OH-DPAT led to a progressive decrease in receptor density with a maximal and statistically significant effect at a concentration of 100 mol/L. Because there were no changes in receptor affinity (K D ) for the radioligand after the preincubation with the agonist, the observed receptor down-regulation was not due to retained agonist binding. Furthermore, the 5-HT 1A receptors downregulation was reversed by the addition of the selective 5-HT 1A receptor antagonist (ϩ)-WAY-100135, confirming that the decrease in receptor density was the result of a specific interaction of 8-OH-DPAT with 5-HT 1A receptors and ruling out the possibility of irreversible agonist binding to the receptor. As compared with the WT and Val28 5-HT 1A receptors, the Ser22 variant displayed a significantly lower degree of agonist-promoted down-regulation. Amino acid substitutions in the putative extracellular amino-terminal region of the ␤ 2 -adrenergic receptor can exert a similar effect on long-term agonist-promoted receptor down-regulation. For ␤ 2 -adrenergic receptors stably transfected in CHW-1102 fibroblasts, substitution of glutamine with glutamic acid at position 27 (Glu27) imparts nearly total resistance to agonist-promoted receptor down-regulation whereas substitution of arginine with glycine at amino acid 16 (Gly16) enhances receptor down-regulation after a 24-h treatment with 10 mol/L isoproterenol (Green et al. 1994) .
We also examined the effect of 5-HT 1A agonist exposure on the ability of the WT 5-HT 1A receptor and the Ser22 and Val28 variants to regulate intracellular cAMP. A 24-h incubation of cells expressing WT or Val28 with 100 mol/L 8-OH-DPAT led to a statistically significant attenuation of the efficacy of 5-HT to inhibit cAMP accumulation. Essentially, no functional desensitization was observed in cells expressing the Ser22 variant. These results suggest that receptor down-regulation and functional desensitization are mechanistically linked in the expressed WT and variant 5-HT 1A receptors. Interestingly, a reduced degree of both agonist-induced down-regulation and functional desensitization has also been reported for the previously mentioned Glu27 ␤ 2 -adrenergic receptor variant endogenously expressed in primary cultures of human airway smooth muscle cells (Green et al. 1995) . The observed alteration in long-term agonist-promoted down-regulation of the Ser22 variant is unlikely to be due to transcriptional differences among the transfected WT, Ser22, and Val28 5-HT 1A receptor genes. Indeed, the plasmids p5-HT 1A SER22 and p5-HT 1A VAL28 differed from the plasmid p5-HT 1A WT only at nucleotides 64 and 82 of the 5-HT 1A gene, respectively. Furthermore, transcription of the receptor genes in the expression vector pcDNA3 was under the control of a viral promoter (CMV) whose activity should not be influenced by agonist-promoted receptor activation. It is possible that the effect of amino-terminal variants on receptor down-regulation is a consequence of altered susceptibility to protein degradation. Cells expressing ␤ 2 -adrenergic receptors (a receptor structurally closely related to the 5-HT 1A receptor) engineered for deletions of amino acids 21-30 in the amino-terminal domain displayed normal ligand binding, but showed an increase in the level of immature receptor (Dixon et al. 1987) . In agreement with these data, the ␤ 2 -adrenergic receptor variant Glu27 expressed in CHW-1102 fibroblasts, that did not undergo long-term agonist-promoted receptor down-regulation, exhibited an altered electrophoretic mobility as compared with the wild type (Green et al. 1994) . This abnormal electrophoretic mobility may reflect an immature conformation of the Glu27 variant that can lead to an alteration of receptor degradation.
Behavioral, electrophysiological, receptor binding, and second messenger studies have provided evidence that down-regulation and/or desensitization of 5-HT 1A receptor occur in vivo as the consequence of prolonged treatment with several classes of antidepressant and anxiolytic drugs, such as SSRIs or 5-HT 1A agonists (Newman et al., 1993; Blier and de Montigny 1994; De Vry 1995; Albert et al. 1996) . The main result of these adaptative changes is an enhancement of serotonergic neurotransmission after approximately 2 weeks. This effect accounts for the therapeutic action of SSRIs or 5-HT 1A agonists as well as the delayed onset of action of these drugs (Blier and de Montigny 1994) . Clinical evidence indicates that blocking 5-HT 1A somatodendritic receptors with the ␤-adrenergic/5-HT 1A antagonist pindolol accelerates the antidepressant effect of SSRIs or monoamino oxidase (MAO) inhibitors and provides a full therapeutic response in patients resistant to antidepressant treatment (Artigas et al. 1994; Blier and Bergeron 1995) . Thus, the resistence to receptor down-regulation and functional desensitization imparted by the Ser22 variant may impair the therapeutic action of widely used antidepressants and anxiolytics. The ␤ 2 -adrenergic receptor variant Gly16, which undergoes an enhanced long-term agonist-mediated down-regulation (Green et al. 1994) , is associated with a requirement for continuous steroid and immuno therapy in asthmatic patients (Reihsaus et al. 1993 ). The enhanced agonist-mediated down-regulation of this ␤ 2 -adrenergic receptor variant may lead to a decreased efficacy of chronic ␤ 2 -adrenergicagonist therapy and explain the need for continuous corticosteroid treatment and immunotherapy (Reihsaus et al. 1993) . Conversely, the Glu27 ␤ 2 -adrenergic receptor variant that imparts resistance to long-term agonistmediated down-regulation (Green et al. 1994) , is associated with lower airway reactivity in asthmatic patients and could have a protective effect against inflammation and bronchoconstriction .
When heterologous expression systems are used to gain insights into receptor regulation, the relevance to in vivo function can be questioned. Regional and cellular specificity of receptor regulation has been reported for the 5-HT 1A receptor expressed in different cerebral areas (Newman et al. 1993; Blier and de Montigny 1994) and in different cell lines (reviewed in Boess and Martin, 1994) . Furthermore, promoter elements that regulate 5-HT 1A receptor expression in native cells are different from those of the viral promoter that controls the transcriptional activity of the 5-HT 1A receptor gene in the eukaryotic expression vector pcDNA3. Nevertheless, the potential usefulness of heterologous recombinant systems for identifying variants altering receptor regulation has been recently supported by the studies on naturally occurring variants in the extracellular amino-terminus of the human ␤ 2 -adrenergic receptor. When the ␤ 2 -adrenergic receptor variants Gly16 and Glu27 were expressed in CHW cells under the control of a viral promoter (Green et al. 1994) , the functional differences observed were consistent with those measured in Gly16 and Glu27 variants endogenously expressed in primary cultures of human airway smooth muscle cells (Green et al. 1995) .
In conclusion, two naturally occurring variants, Ser22 and Val28, in the putative amino-terminal region of the 5-HT 1A receptor do not alter receptor ligand binding and coupling to second messengers. However, Ser22 alters long-term agonist-promoted receptor downregulation and functional desensitization. Taking into account the limitations that arise from the in vitro design of this study, we speculate that the relative resistence of the variant Ser22 5-HT 1A to receptor downregulation and functional desensitization could modify the regulatory properties of the receptor in vivo and lead to altered sensitivity of the 5-HT 1A receptor to antidepressant and anxiolytic treatment in individuals who carry this rare 5-HT 1A receptor variant.
